Informed-money record
CTMX · CytomX Therapeutics, Inc.
Disclosed informed-money activity on this name over the last 12 months — corporate insiders, institutions, and members of Congress, from public-domain SEC and congressional filings. A dated factual record with receipts; interpretation is yours.
Bullish filings
0
Bearish filings
9
Named actors
5
Disclosed $ (bull / bear)
$0 / $2.2M
Recent disclosures
9 of 9 in the window · linked to source| Date | Who | What | Disclosed $ | Receipt |
|---|---|---|---|---|
| 2026-03-27 | Chief Executive Officer and Chairman Sean McCarthy | adopted a selling plan | — | SEC ↗ |
| 2026-03-18 | Issuer (share issuance) | priced an offering | — | SEC ↗ |
| 2026-03-17 | Chief Financial Officer Ogden Christopher | sold | $124K | SEC ↗ |
| 2026-03-17 | SVP, Chief Scientific Officer BELVIN MARCIA | sold | $202K | SEC ↗ |
| 2026-03-17 | CEO McCarthy Sean A. | sold | $764K | SEC ↗ |
| 2026-03-17 | Chief Medical Officer Chu Yu-Waye | sold | $137K | SEC ↗ |
| 2026-03-16 | Issuer (share issuance) | priced an offering | — | SEC ↗ |
| 2025-11-06 | CEO McCarthy Sean A. | sold | $462K | SEC ↗ |
| 2025-11-06 | CEO (via Merrill Lynch) Sean McCarthy | filed notice to sell | $462K | SEC ↗ |
Want the read, not just the record?
Members see how notable each move is, whether the actor's track record validates, cross-source convergence, and alerts on this name.
Create a free account →Dispute or correct this record
Events dated by when the activity occurred (a trade's transaction date; a notice, stake, or announcement at its filing date); the linked filing is the authoritative record. Directional public-domain disclosures only. Descriptive, not investment advice. Methodology · Today's notable signals